Latest period
$5.70B
YoY change
+6.4%
5Y CAGR
+12.6%
Peak year (2013)
$17.49B
Latest annual
$14.56B
Cash on Hand history chart for Merck & Co. (MRK) from 1985 to 2025
Latest: $14.56B
Cash on Hand growth chart for Merck & Co. (MRK) from 1985 to 2025
Latest: +6.4%
Cash on Hand history table for Merck & Co. (MRK) from 1985 to 2025
| 2025 | $14.56B | +6.4% | +$876.00M | ||
| 2024 | $13.69B | +93.0% | +$6.60B | ||
| 2023 | $7.09B | -46.2% | −$6.10B | ||
| 2022 | $13.19B | +62.9% | +$5.10B | ||
| 2021 | $8.10B | +0.6% | +$46.00M | ||
| 2020 | $8.05B | -23.0% | −$2.40B | ||
| 2019 | $10.45B | +17.9% | +$1.59B | ||
| 2018 | $8.86B | +4.3% | +$366.00M | ||
| 2017 | $8.50B | -40.7% | −$5.84B | ||
| 2016 | $14.34B | +6.8% | +$914.00M | ||
| 2015 | $13.43B | -14.6% | −$2.29B | ||
| 2014 | $15.72B | -10.1% | −$1.77B | ||
| 2013 | $17.49B | +8.3% | +$1.34B | ||
| 2012 | $16.14B | +7.8% | +$1.17B | ||
| 2011 | $14.97B | +22.7% | +$2.77B | ||
| 2010 | $12.20B | +27.0% | +$2.60B | ||
| 2009 | $9.60B | +75.1% | +$4.12B | ||
| 2008 | $5.49B | -33.3% | −$2.74B | ||
| 2007 | $8.23B | -5.5% | −$482.20M | ||
| 2006 | $8.71B | -44.3% | −$6.92B | ||
| 2005 | $15.64B | +120.6% | +$8.55B | ||
| 2004 | $7.09B | +69.9% | +$2.92B | ||
| 2003 | $4.17B | -16.1% | −$798.20M | ||
| 2002 | $4.97B | +51.3% | +$1.68B | ||
| 2001 | $3.29B | -22.8% | −$968.00M | ||
| 2000 | $4.25B | +32.9% | +$1.05B | ||
| 1999 | $3.20B | +22.9% | +$596.20M | ||
| 1998 | $2.61B | +131.6% | +$1.48B | ||
| 1997 | $1.13B | -16.8% | −$227.30M | ||
| 1996 | $1.35B | -26.8% | −$495.00M | ||
| 1995 | $1.85B | +15.2% | +$243.40M | ||
| 1994 | $1.60B | +93.4% | +$774.60M | ||
| 1993 | $829.40M | +44.2% | +$254.30M | ||
| 1992 | $575.10M | -27.9% | −$222.80M | ||
| 1991 | $797.90M | -1.1% | −$8.50M | ||
| 1990 | $806.40M | +17.7% | +$121.30M | ||
| 1989 | $685.10M | -55.8% | −$864.90M | ||
| 1988 | $1.55B | +35.0% | +$401.80M | ||
| 1987 | $1.15B | +18.9% | +$182.40M | ||
| 1986 | $965.80M | +14.7% | +$123.80M | ||
| 1985 | $842.00M | — | — |
- 2025$14.56B+6.4%
- 2024$13.69B+93.0%
- 2023$7.09B-46.2%
- 2022$13.19B+62.9%
- 2021$8.10B+0.6%
- 2020$8.05B-23.0%
- 2019$10.45B+17.9%
- 2018$8.86B+4.3%
- 2017$8.50B-40.7%
- 2016$14.34B+6.8%
- 2015$13.43B-14.6%
- 2014$15.72B-10.1%
- 2013$17.49B+8.3%
- 2012$16.14B+7.8%
- 2011$14.97B+22.7%
- 2010$12.20B+27.0%
- 2009$9.60B+75.1%
- 2008$5.49B-33.3%
- 2007$8.23B-5.5%
- 2006$8.71B-44.3%
- 2005$15.64B+120.6%
- 2004$7.09B+69.9%
- 2003$4.17B-16.1%
- 2002$4.97B+51.3%
- 2001$3.29B-22.8%
- 2000$4.25B+32.9%
- 1999$3.20B+22.9%
- 1998$2.61B+131.6%
- 1997$1.13B-16.8%
- 1996$1.35B-26.8%
- 1995$1.85B+15.2%
- 1994$1.60B+93.4%
- 1993$829.40M+44.2%
- 1992$575.10M-27.9%
- 1991$797.90M-1.1%
- 1990$806.40M+17.7%
- 1989$685.10M-55.8%
- 1988$1.55B+35.0%
- 1987$1.15B+18.9%
- 1986$965.80M+14.7%
- 1985$842.00M—
Cash on Hand values are taken from Merck & Co.'s reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Cash on Hand at Merck & Co. (MRK)
According to Merck & Co.'s latest reported financial statements, the company's latest reported cash and short-term investments is $5.70B. Cash on hand here is cash, cash equivalents, and short-term investments reported at the end of each period — the most liquid assets on the balance sheet. Compare with total debt for net leverage and total assets for the share of assets held in cash.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
Merck & Co. (MRK) most recent annual cash and short-term investments stands at $14.56B (2025) – grew 6.4% year-over-year.
Merck & Co. cash and short-term investments compound annual growth for the 2020–2025 (5 years) window is +12.6%, sustaining 2 straight years of year-over-year growth.
Merck & Co. cash and short-term investments declined from $17.49B in 2013 to $14.56B in 2025, a 16.7% drawdown.
$17.49B stands as the all-time-high annual cash and short-term investments, posted in 2013, against a low of $575.10M during 1992.
Merck & Co. Cash on Hand by Year
Merck & Co. Cash on Hand 2025: $14.56B
Merck & Co. posted cash and short-term investments of $14.56B in 2025, grew 6.4% from 2024.
Merck & Co. Cash on Hand 2024: $13.69B
In 2024, Merck & Co. reported cash and short-term investments of $13.69B, surged 93.0% from 2023.
Merck & Co. Cash on Hand 2023: $7.09B
Merck & Co. cash and short-term investments in 2023 was $7.09B, plunged 46.2% below 2022.
Merck & Co. Cash on Hand 2022: $13.19B
2022's cash and short-term investments for Merck & Co. came in at $13.19B, surged 62.9% from 2021.
Merck & Co. Cash on Hand 2021: $8.10B
Merck & Co. cash and short-term investments in 2021 was $8.10B.
See more financial history for Merck & Co. (MRK).
Sector peers by Cash on Hand
Healthcare peers of Merck & Co. (MRK), ranked by their latest cash and short-term investments
| $28.12B | |
| $20.10B | |
| $10.11B | |
| $9.13B | |
| $7.27B | |
| $5.74B | |
| $5.26B | |
| $4.24B |
- $28.12B
- $20.10B
- $9.13B
- $7.27B
- $5.74B
- $5.26B
- $4.24B
Frequently asked questions
Merck & Co. (MRK) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation